{"disease":{"id":"folliculotropic-mycosis-fungoides","name":"folliculotropic mycosis fungoides"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03011814","title":"Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":38,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT04930653","title":"Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":34,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT03380026","title":"Mechlorethamine Induced Contact Dermatitis Avoidance Study","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"Rochester Skin Lymphoma Medical Group, PLLC","has_results":true}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}